← Back to Search

HMG-CoA reductase inhibitor

Atorvastatin for Heart Failure in Patients Receiving Anthracycline (SPARE-HF Trial)

Phase 2
Waitlist Available
Led By Paaladinesh Thavendiranathan
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 4 weeks of anthracycline completion

Summary

This trial tests if taking atorvastatin before and during chemotherapy can prevent heart problems in cancer patients. It focuses on those with existing heart risk factors. Statins may help by reducing inflammation and protecting heart cells from damage caused by chemotherapy. Atorvastatin, a statin, is widely used to lower blood cholesterol and reduce cardiovascular disease risk, and recent studies suggest it may also help reduce heart problems in cancer patients undergoing chemotherapy.

Eligible Conditions
  • Cardiotoxicity
  • Heart Failure
  • Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 4 weeks of anthracycline completion
This trial's timeline: 3 weeks for screening, Varies for treatment, and within 4 weeks of anthracycline completion for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Cardiac MRI measured LVEF within 4 weeks of anthracycline completion
Other study objectives
BNP
Cardiac MRI measured LV end diastolic volume (LVEDV) and end systolic volume (LVESV) at the end of treatment
Interruption of study drug due to side effects or permanent cessation of study drug or cancer treatment due to cardiac dysfunction
+4 more

Side effects data

From 2014 Phase 3 trial • 58 Patients • NCT02084069
3%
Postoperative bleeding
100%
80%
60%
40%
20%
0%
Study treatment Arm
Treatment
Control

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: StatinExperimental Treatment1 Intervention
Atorvastatin 40mg
Group II: PlacebosPlacebo Group1 Intervention
Placebos
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Atorvastatin
1998
Completed Phase 4
~10900

Find a Location

Who is running the clinical trial?

Mount Sinai Hospital, CanadaOTHER
204 Previous Clinical Trials
69,085 Total Patients Enrolled
Sunnybrook Health Sciences CentreOTHER
681 Previous Clinical Trials
1,565,646 Total Patients Enrolled
Unity Health TorontoOTHER
562 Previous Clinical Trials
453,839 Total Patients Enrolled
2 Trials studying Cardiotoxicity
385 Patients Enrolled for Cardiotoxicity
Scarborough General HospitalOTHER
10 Previous Clinical Trials
6,357 Total Patients Enrolled
University Health Network, TorontoLead Sponsor
1,531 Previous Clinical Trials
504,210 Total Patients Enrolled
5 Trials studying Cardiotoxicity
883 Patients Enrolled for Cardiotoxicity
Paaladinesh ThavendiranathanPrincipal InvestigatorUniversity Health Network, Toronto
Eitan AmirPrincipal InvestigatorUniversity Health Network, Toronto

Media Library

Atorvastatin (HMG-CoA reductase inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT03186404 — Phase 2
Cardiotoxicity Research Study Groups: Placebos, Statin
Cardiotoxicity Clinical Trial 2023: Atorvastatin Highlights & Side Effects. Trial Name: NCT03186404 — Phase 2
Atorvastatin (HMG-CoA reductase inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03186404 — Phase 2
~15 spots leftby Jan 2026